» Hinton » Home 


Division Prof. Dr. Jim Hinton

Research in the division covers two main areas: high-energy astrophysics exploring the sources and acceleration processes of high-energy particles in the Universe, and particle physics probing the Standard Model.

High energy astrophysics employs atmospheric Cherenkov telescopes or dense particle detector arrays to measure gamma rays emitted by high-energy particles in our Galaxy and beyond. The division has contributed major parts of the hardware of the H.E.S.S. Cherenkov telescopes and the HAWC high-energy extension, and plays a significant role in preparing the next generation Cherenkov Telescope Array CTA. Associated research groups cover theory and phenomenology of high energy astrophysics, theoretical astrophysics and infrared astrophysics.

Accelerator-based particle physics projects are primarily aimed at the study of heavy-quark production and decays, with emphasis on the phase space relevant to both particle physics and cosmic-ray physics.

The GERDA experiment at the Gran Sasso underground laboratory investigates neutrinoless double-beta decay of 76Ge, probing mass and nature of neutrinos.


Cosmic ray particles and VHE photons
Detection of extensive air showers
Astroparticle physics in underground labs

Current projects

H.E.S.S. – An array of large imaging atmospheric Cherenkov telescopes
CTA – An advanced facility for ground-based gamma-ray astrophysics
GERDA/LEGEND – Search for the neutrinoless double-β decay
HAWC – A wide field-of-view TeV gamma-ray observatory
SWGO – A southern TeV gamma-ray observatory
LHCb – Precision physics at the terascale

Associated research activities


Max Planck Institute
for Nuclear Physics
Saupfercheckweg 1
69117 Heidelberg

Non-thermal Astrophysics

Prof. Dr. Jim Hinton

Ruth Crespo
Phone +49 6221 516-201
Fax +49 6221 516-603
AT mpi-hd.mpg.de



Der Neutrinomasse auf den Fersen

Seit 2010 fahndet das GERDA-Experiment nach einem extrem...


FlashCam-Elektronik hilft Ionenstrahltherapie zu verbessern

Bei der Ionenstrahltherapie ist es das Ziel, malignes...